SpringWorks Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, SpringWorks Therapeutics sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
SpringWorks Therapeutics: 7 sponsored US clinical trials, 3 recruiting.
SpringWorks Therapeutics sponsors 7 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 2 completed. 1 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 2 trials.
Upper-quartile sponsor footprint
SpringWorks Therapeutics sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat
NCT07171619
Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib
NCT06997276
SW-682 in Advanced Solid Tumors
NCT06251310
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas
NCT03962543
Mirdametinib + BGB-3245 in Advanced Solid Tumors
NCT05580770
Nirogacestat in Ovarian Granulosa Cell Tumors
NCT05348356
Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
NCT03785964
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 2 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the SpringWorks Therapeutics pipeline
3 recruiting of 7 indexed (43% open); 2 completed (29%).
Phase mix: 1 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Healthy (2 trials), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
SpringWorks Therapeutics: open-pipeline peers nationwide
Peers matched on 7 registered trials and 43% open enrollment, not the therapeutic-area sidebar.
SpringWorks Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 43% open enrollment (± trial volume)
- Alphatec Spine · 43% recruiting · 7 trials
- Clarity Pharmaceuticals · 43% recruiting · 7 trials
- Colorado Center for Reproductive Medicine · 43% recruiting · 7 trials
- David Moss · 43% recruiting · 7 trials
Related
What to do with this SpringWorks Therapeutics page
7 registered trials is a research-attention snapshot, not an endorsement of SpringWorks Therapeutics or any single study.
- 3 of SpringWorks Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition SpringWorks Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. SpringWorks Therapeutics pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.